Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367783
Status:
TERMINATED
Last Update Posted:
2011-08-01
First Post:
2006-05-30
Brief Title:
Safety Toleration and Efficacy of CP-741952 for the Treatment of Obesity
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A 12-Week Phase 2A Randomized Subject And Investigator Blind Placebo-Controlled Trial To Evaluate The Effect Of CP-741952 On Weight Loss In Otherwise Healthy Overweight And Obese Adult Subjects
Status:
TERMINATED
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See Detailed Description for termination reason
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether CP-741952 is effective in the treatment of obesity and to determine 12 week safety and toleration
Detailed Description:
Following review of the preliminary data from completed study A7081004 the development program for CP-741952 was terminated on 15 March 2007 Primary reasons for program termination included a lack of significant efficacy at all doses investigated and an increased incidence of mild to moderate elevations in serum transaminases primarily alanine aminotransferase ALT and liver fat content in treated compared to placebo subjects A synopsis will be created and will include greater detail on these findings
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None